October 30, 2026
The US Food and Drug Administration (FDA) has approved Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis?utm_content=388760332&utm_medium=social&utm_source=linkedin&hss_channel=lcp-37897480